Search results for "Vaccines"

showing 10 items of 554 documents

Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines

2015

Abstract Somatic mutations binding to the patient's MHC and recognized by autologous T cells (neoepitopes) are ideal cancer vaccine targets. They combine a favorable safety profile due to a lack of expression in healthy tissues with a high likelihood of immunogenicity, as T cells recognizing neoepitopes are not shaped by central immune tolerance. Proteins mutated in cancer (neoantigens) shared by patients have been explored as vaccine targets for many years. Shared (“public”) mutations, however, are rare, as the vast majority of cancer mutations in a given tumor are unique for the individual patient. Recently, the novel concept of truly individualized cancer vaccination emerged, which explo…

0301 basic medicineCancer ResearchBioinformaticsmedicine.disease_causeMajor histocompatibility complexCancer VaccinesEpitopeTranslational Research BiomedicalEpitopesGenetic Heterogeneity03 medical and health sciences0302 clinical medicineAntigenAntigens NeoplasmNeoplasmsAnimalsHumansMedicineClinical Trials as TopicMutationbiologybusiness.industryGenetic heterogeneityGenetic VariationCancermedicine.diseaseAntigenic VariationVaccination030104 developmental biologyOncology030220 oncology & carcinogenesisMutationbiology.proteinCancer vaccinebusinessClinical Cancer Research
researchProduct

Reduced Breast Tumor Growth after Immunization with a Tumor-Restricted MUC1 Glycopeptide Conjugated to Tetanus Toxoid.

2018

Abstract Preventive vaccination against tumor-associated endogenous antigens is considered to be an attractive strategy for the induction of a curative immune response concomitant with a long-lasting immunologic memory. The mucin MUC1 is a promising tumor antigen, as its tumor-associated form differs from the glycoprotein form expressed on healthy cells. Due to aberrant glycosylation in tumor cells, the specific peptide epitopes in its backbone are accessible and can be bound by antibodies induced by vaccination. Breast cancer patients develop per se only low levels of T cells and antibodies recognizing tumor-associated MUC1, and clinical trials with tumor-associated MUC1 yielded unsatisfac…

0301 basic medicineCancer ResearchImmunologyMice TransgenicTriple Negative Breast NeoplasmsCancer Vaccines03 medical and health sciences0302 clinical medicineImmune systemAntigenCell Line TumorTetanus ToxoidMedicineAnimalsHumansskin and connective tissue diseasesMUC1Vaccines Syntheticbiologybusiness.industryMucin-1ToxoidGlycopeptidesAntibodies MonoclonalMammary Neoplasms ExperimentalMiddle AgedTumor antigen030104 developmental biologyImmunizationTumor progression030220 oncology & carcinogenesisImmunoglobulin Gbiology.proteinCancer researchFemaleAntibodybusinessCancer immunology research
researchProduct

Le cancer du col de l’utérus : état des lieux et prévention au Maroc

2019

With more than 3300 new cases and almost 2500 deaths each year, cervical cancer (CC) ranks second among female cancers in Moroccan women. The majority of cases occurs in women aged 50 and over. In absence of a national cancer registry, data published in Morocco are limited to the number of cases recorded in some oncology centers, so the incidence of this cancer is likely much higher than estimated. A Moroccan national program against CC based on the practice of visual inspection after application of acetic acid was set up in 2010, allowing both screening and possibly immediate treatment of (pre)cancerous lesions. However, this program has not been implemented in all regions of the country. …

0301 basic medicineCancer Researchmedicine.medical_specialty[SDV]Life Sciences [q-bio]Disease03 medical and health sciencesPapillomavirus Vaccines0302 clinical medicinemedicineRadiology Nuclear Medicine and imagingGynecologyCervical cancerbusiness.industryIncidence (epidemiology)HPV infectionCancerHematologyGeneral Medicinemedicine.disease3. Good healthCancer registry030104 developmental biologyOncology030220 oncology & carcinogenesisCoinfectionbusiness
researchProduct

Immune response to tick-borne hemoparasites: Host adaptive immune response mechanisms as potential targets for therapies and vaccines

2020

This article belongs to the Section Molecular Immunology.

0301 basic medicineChemokine030106 microbiologyReviewAdaptive ImmunityBiologyCatalysisEpitopeInorganic Chemistry03 medical and health sciencesImmune systemAntigenmedicineAnimalsHumansCytotoxic T cellPhysical and Theoretical ChemistryAntigensMolecular BiologySpectroscopyVaccinesHost Microbial InteractionsEffectorOrganic ChemistryGeneral MedicineT helper cellAcquired immune systemTick-borne hemoparasitesComputer Science Applications030104 developmental biologymedicine.anatomical_structureAdaptive immune response Antigens Tick-borne hemoparasitesTick-Borne DiseasesImmunologybiology.proteinAdaptive immune response
researchProduct

Self-adjuvanting C18 lipid vinil sulfone-PP2A vaccine: study of the induced immunomodulation against Trichuris muris infection

2017

Despite the importance of the adjuvant in the immunization process, very few adjuvants merge with the antigens in vaccines. A synthetic self-adjuvant oleic-vinyl sulfone (OVS) linked to the catalytic region of recombinant serine/threonine phosphatase 2A from the nematode Angiostrongylus costaricensis (rPP2A) was used for intranasal immunization in mice previously infected with Trichuris muris . The animal intranasal immunization with rPP2A-OVS showed a reduction of 99.01% in the number of the nematode eggs and 97.90% in adult. The immunohistochemical analysis of the intestinal sections showed that in immunized animals with lipopeptide the mucus was significantly higher than in the other ex…

0301 basic medicineChemokinemedicine.medical_treatmentGene ExpressionchemokinesTrichuris murisMicechemistry.chemical_compound0302 clinical medicineIntestinal mucosaProtein Phosphatase 2SulfonesIntestinal Mucosalcsh:QH301-705.5biologyGeneral NeuroscienceLipopeptideHelminth Proteinstrichuris muris vaccinationRecombinant ProteinsTrichurisFemaleAdjuvantAngiostrongylus costaricensisself-assembling lipopeptide rPP2AChemokine CCL11Immunologychemical and pharmacologic phenomenaself-assembling lipopeptide rpp2aGeneral Biochemistry Genetics and Molecular BiologyMicrobiologyLipopeptidesMice Inbred AKR03 medical and health sciencesAdjuvants ImmunologicAntigenmedicineAnimalsAmino Acid SequenceTrichuriasislipid vinyl sulfoneParasite Egg CountAdministration IntranasalChemokine CCL20Vaccines ConjugateInterleukinsbiology.organism_classificationMucusTrichuris muris vaccinationcytokines030104 developmental biologychemistrylcsh:Biology (General)Immunologybiology.proteinTh17 CellsSequence Alignment030215 immunology
researchProduct

Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma

2016

The development of nucleic acid based vaccines against cancer has gained considerable momentum through the advancement of modern sequencing technologies and on novel RNA-based synthetic drug formats, which can be readily adapted following identification of every patient's tumor-specific mutations. Furthermore, affordable and individual ‘on demand’ production of molecularly optimized vaccines should allow their application in large groups of patients. This has resulted in the therapeutic concept of an active personalized cancer vaccine, which has been brought into clinical testing. Successful trials have been performed by intranodal administration of sterile isotonic solutions of synthetic …

0301 basic medicineDrugmedicine.medical_treatmentmedia_common.quotation_subjectBiomedical EngineeringMedicine (miscellaneous)Bioengineering02 engineering and technologyComputational biologyDevelopmentPharmacologyCancer VaccinesExcipients03 medical and health sciencesAntigens NeoplasmmedicineAnimalsHumansGeneral Materials ScienceRNA MessengerPrecision MedicineMelanomamedia_commonClinical Trials as TopicMessenger RNAbusiness.industryRNAImmunotherapy021001 nanoscience & nanotechnologyTumor antigenNanomedicine030104 developmental biologyLiposomesDrug deliveryNucleic acidNanoparticlesRNAImmunotherapyCancer vaccine0210 nano-technologybusinessNanomedicine
researchProduct

Exploiting Helminth–Host Interactomes through Big Data

2017

Helminths facilitate their parasitic existence through the production and secretion of different molecules, including proteins. Some helminth proteins can manipulate the host's immune system, a phenomenon that is now being exploited with a view to developing therapeutics for inflammatory diseases. In recent years, hundreds of helminth genomes have been sequenced, but as a community we are still taking baby steps when it comes to identifying proteins that govern host-helminth interactions. The information generated from genomic, immunomic, and proteomic studies, as well as from cutting-edge approaches such as proteogenomics, is leading to a substantial volume of big data that can be utilised…

0301 basic medicineGenome HelminthVaccinesHost (biology)business.industryHelminth proteinBig dataComputational BiologyHelminth ProteinsComputational biologyBiologyProteogenomicsHelminth GenomesProteomicsBioinformaticsHost-Parasite Interactions03 medical and health sciences030104 developmental biologyInfectious Diseasesparasitic diseasesAnimalsHumansParasitologybusinessTrends in Parasitology
researchProduct

MPLA-coated hepatitis B virus surface antigen (HBsAg) nanocapsules induce vigorous T cell responses in cord blood derived human T cells.

2016

Chronic hepatitis B virus (HBV) infection is the most prevalent serious liver infection in the world. A frequent route of infection represents mother-to-child transmission. Efficient control of HBV replication depends on antigen-specific cellular immune response mediated by dendritic cells (DCs). Aim of the present study was to evaluate optimized adjuvant combinations, efficiently maturing monocyte-derived neonatal and adult dendritic cells (moDCs). In addition, the potential of polymeric HBsAg-nanocapsules (HBsAg-NCs) was investigated regarding up-take by moDCs and the subsequent induction of specific T cell responses in a human co-culture model. Simultaneous stimulation of moDCs with MPLA…

0301 basic medicineHBsAgHepatitis B virusT cellT-LymphocytesBiomedical EngineeringPharmaceutical ScienceMedicine (miscellaneous)Bioengineeringmedicine.disease_causeVirus03 medical and health sciences0302 clinical medicineImmune systemNanocapsulesmedicineHumansGeneral Materials ScienceHepatitis B VaccinesHepatitis B virusLiver infectionHepatitis B Surface Antigensbusiness.industryDendritic CellsHepatitis Bmedicine.diseaseFetal BloodHepatitis BVirology030104 developmental biologymedicine.anatomical_structureImmunologyAntigens SurfaceMolecular MedicinebusinessCD80030215 immunologyNanomedicine : nanotechnology, biology, and medicine
researchProduct

Novel strategies in vaccine design: can nanocapsules help prevent and treat hepatitis B?

2017

0301 basic medicineHepatitis B virusBiomedical EngineeringMedicine (miscellaneous)BioengineeringDevelopmentmedicine.disease_causeHepatitis b surface antigenNanocapsules03 medical and health sciences0302 clinical medicineNanocapsulesmedicineHumansGeneral Materials ScienceHepatitis B Vaccines030212 general & internal medicineHepatitis B virusHepatitis B Surface Antigensbusiness.industryHepatitis Bmedicine.diseaseHepatitis BVirologyVaccination030104 developmental biologyImmunizationImmunizationbusinessNanomedicine (London, England)
researchProduct

Efficient Delivery of Human Cytomegalovirus T Cell Antigens by Attenuated Sendai Virus Vectors.

2018

ABSTRACT Human cytomegalovirus (HCMV) represents a major cause of clinical complications during pregnancy as well as immunosuppression, and the licensing of a protective HCMV vaccine remains an unmet global need. Here, we designed and validated novel Sendai virus (SeV) vectors delivering the T cell immunogens IE-1 and pp65. To enhance vector safety, we used a replication-deficient strain (rdSeV) that infects target cells in a nonproductive manner while retaining viral gene expression. In this study, we explored the impact that transduction with rdSeV has on human dendritic cells (DCs) by comparing it to the parental, replication-competent Sendai virus strain (rcSeV) as well as the poxvirus …

0301 basic medicineHuman cytomegalovirusModified vaccinia AnkaraT cellmedicine.medical_treatmentvirusesImmunologyGenetic VectorsAlpha interferonCytomegalovirusMice TransgenicMicrobiologySendai virusViral Matrix Proteins03 medical and health sciencesCytomegalovirus VaccinesMiceTransduction GeneticVirologyCricetinaeChlorocebus aethiopsVaccines and Antiviral AgentsmedicineCytotoxic T cellAnimalsHumansAntigens ViralVero Cellsbiologyvirus diseasesImmunotherapymedicine.diseasebiology.organism_classificationPhosphoproteinsVirologySendai virus030104 developmental biologymedicine.anatomical_structureViral replicationInsect ScienceJournal of virology
researchProduct